Compare PGEN & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | SGRY |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2013 | 2015 |
| Metric | PGEN | SGRY |
|---|---|---|
| Price | $4.21 | $26.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | $13.67 | ★ $24.40 |
| AVG Volume (30 Days) | 6.8M | ★ 6.9M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.14 |
| EPS | ★ 0.12 | N/A |
| Revenue | $230,981,000.00 | ★ $1,145,438,000.00 |
| Revenue This Year | $2,380.31 | N/A |
| Revenue Next Year | $84.01 | N/A |
| P/E Ratio | $34.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.04 | $11.41 |
| 52 Week High | $8.98 | $27.23 |
| Indicator | PGEN | SGRY |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 84.80 |
| Support Level | $3.89 | $13.26 |
| Resistance Level | $4.41 | $27.23 |
| Average True Range (ATR) | 0.36 | 0.35 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 16.78 | 89.89 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.